Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference36 articles.
1. Zhang W, Amos TB, Gutkin SW, Lodowski N, Giegerich E, Joshi K. A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. Clinicoecon Outcomes Res. 2018;10:309.
2. Kang SJ, Ko SH, Kim JY, Kim SR. Effects of a mental fitness positive psychology intervention program on inpatients with schizophrenia in South Korea: a feasibility study. Perspect Psychiatr Care. 2018. https://doi.org/10.1111/ppc.12332.
3. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44:1195–203.
4. Chiou C-F, Wang BC, Caldwell R, Furnback W, Lee J-S, Kothandaraman N, et al. The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia. Neuropsychiatr Dis Treat. 2015;11:1989.
5. Kim W, Jang SY, Chun SY, Lee TH, Han KT, Park EC. Mortality in schizophrenia and other psychoses: data from the South Korea National Health Insurance Cohort, 2002–2013. J Korean Med Sci. 2017;32:835–42. https://doi.org/10.3346/jkms.2017.32.5.835.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献